AUTH/2527/8/12: Anonymous v Shire — alleged pre-licence promotion via MSLs and advisory boards (No breach) | PMCPA Case

📊

Key facts

⌄

Case number	AUTH/2527/8/12
Complainant	Anonymous, non-contactable (self-described health professional managing ADHD)
Company	Shire Pharmaceuticals Limited
Medicine(s)	Vyvance/Vyvanse (lisdexamphetamine mesylate, LDX) (unlicensed in UK at the time); Equasym XL (methylphenidate extended release) mentioned as marketed product
Issue	Alleged promotion prior to grant of a marketing authorisation; alleged “noise” creation, targets, and named-patient encouragement; concerns about repeated advisory boards
Applicable Code year	2012
Clauses considered	2, 3.1 and 9.1
Decision	No breach
Complaint received	6 August 2012
Case completed	15 October 2012
Appeal	No appeal
Panel observations (non-breach)	Concerns about clarity of “reactive-only” restrictions in some materials; ambiguity in MSL guidance about proactive vs reactive on-label discussions; concerns about number/overlap of advisory boards

Download the full case report (PDF)

Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI

🎬 Expert Video Walkthrough

🎬

Video walkthrough — coming for members

Subscribe now and get expert video analysis for every case as we publish them.

Subscribe — from £299/yr

📋

What happened

⌄

An anonymous, non-contactable complainant (self-described health professional managing ADHD) alleged a Shire medical science liaison (MSL) discussed an amphetamine medicine not licensed in the UK, planned for launch the following year: Vyvance/Vyvanse (lisdexamphetamine mesylate, LDX).
The complainant alleged Shire instructed MSLs to create “noise” in the market about LDX, with quarterly targets including numbers of physicians “ready to write prescriptions” and specialists willing to speak about the medicine.
The complainant further alleged Shire encouraged specialists to try LDX via a named-patient scheme (with patients paying privately).
The complainant also raised concerns about a consultant colleague attending multiple two-day monthly advisory panel meetings (third or fourth in 2012), implying this could drive future prescribing.
Shire denied all allegations, stating MSLs were non-promotional, not sales-incentivised, had no targets for HCP interactions, and only provided LDX information reactively in response to unsolicited requests.
Shire stated LDX could be obtained via a third-party importer on a named-patient basis where lawful, but Shire did not promote or encourage named-patient supply; details of an importer could be provided only “if pressed” by an enquiring HCP.
The Panel reviewed Shire’s MSL role documents and LDX briefing materials, and considered the advisory board programme (ten UK ADHD-related advisory boards since January 2011, plus international boards).

⚖️

Outcome

⌄

No breach of the Code was ruled.
The Panel found the complainant provided little information and no documentation; allegations were not proven on the balance of probabilities.
The Panel had concerns about clarity and controls in some internal materials (eg whether certain content was clearly restricted to reactive use), but concluded there was no evidence of pre-licence promotion or promotion of named-patient supply.
On the narrow grounds alleged, the Panel also ruled no breach regarding advisory boards promoting LDX pre-authorisation.

🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value

£249/year

Annual — save £99

£29/mo

Monthly

Join Now — Instant Access

AUTH/2527/8/12: Anonymous v Shire — alleged pre-licence promotion via MSLs and advisory boards (No breach)

Key facts

What happened

Outcome

Clauses

Unlock the full case analysis

AQP Flagship Path — the complete UK ABPI signatory programme

📰 Weekly PMCPA Case Breakdown